​

DexCom (DXCM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DXCM Stock Forecast

DexCom (DXCM) stock forecast, based on 50 Wall Street analysts, predicts a 12-month average price target of $94.67, with a high of $100.00 and a low of $90.00. This represents a 34.04% increase from the last price of $70.63.

$65 $80 $95 $110 $125 $140 High: $100 Avg: $94.67 Low: $90 Last Closed Price: $70.63

DXCM Stock Rating

DexCom stock's rating consensus is Buy, based on 50 Wall Street analysts. The breakdown includes 1 Strong Buy (2.00%), 38 Buy (76.00%), 10 Hold (20.00%), 1 Sell (2.00%), and 0 Strong Sell (0.00%).

Buy
Total 50 10 38 1 Strong Sell Sell Hold Buy Strong Buy

DXCM Price Target Upside V Benchmarks

TypeNameUpside
StockDexCom34.04%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks18.84%

Price Target Trends

1M3M12M
# Anlaysts233
Avg Price Target$97.00$94.67$94.67
Last Closing Price$70.63$70.63$70.63
Upside/Downside37.34%34.04%34.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 254194--27
Sep, 253204--27
Aug, 253194--26
Jul, 255193--27
Jun, 256173--26
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2025Matt O'BrienPiper Sandler$100.00$68.4446.11%41.58%
Oct 15, 2025Richard NewitterTruist Financial$94.00$65.5543.40%33.09%
Sep 26, 2025Robert W. Baird$90.00$68.3031.77%27.42%
Oct 08, 2024Shagun SinghRBC Capital$120.00$68.6274.88%69.90%
Aug 22, 2024Mathew BlackmanStifel Nicolaus$100.00$72.2838.35%41.58%
Aug 16, 2024Shagun SinghRBC Capital$130.00$72.3679.66%84.06%
Jul 29, 2024Matt MiksicBarclays$113.00$64.0076.56%59.99%
Jul 26, 2024Steven LichtmanOppenheimer$115.00$107.856.63%62.82%
Jul 26, 2024Matt O\'BrienPiper Sandler$90.00$63.2242.36%27.42%
Jul 26, 2024William PlovanicCanaccord Genuity$89.00$107.85-17.48%26.01%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2025Cowen & Co.BuyBuyhold
Oct 21, 2025Piper SandlerOverweightOverweighthold
Sep 08, 2025OppenheimerOutperformPerformdowngrade
May 22, 2025CitigroupBuyBuyhold
May 02, 2025Piper SandlerOverweightOverweighthold
Mar 08, 2025Wells FargoOverweightOverweighthold
Jan 08, 2025BernsteinOutperformOutperformhold
Dec 11, 2024CitigroupBuyBuyhold
Oct 22, 2024Piper SandlerOverweightOverweighthold
Oct 08, 2024RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.31$0.56$0.88$1.40-----
Avg Forecast$0.76$0.71$0.80$1.44$1.69$2.02$2.45$3.11$3.85
High Forecast$0.78$0.73$0.81$1.48$1.74$2.19$2.77$3.26$3.89
Low Forecast$0.75$0.69$0.78$1.40$1.60$1.79$2.01$2.95$3.82
Surprise %72.37%-21.13%10.00%-2.78%-----

Revenue Forecast

$2B $3B $4B $5B $6B $8B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.93B$2.45B$2.91B$3.62B-----
Avg Forecast$1.91B$2.45B$2.91B$3.60B$4.02B$4.61B$5.31B$6.26B$7.15B
High Forecast$1.95B$2.50B$2.93B$3.63B$4.03B$4.65B$5.31B$6.30B$7.21B
Low Forecast$1.88B$2.41B$2.87B$3.58B$4.00B$4.59B$5.30B$6.22B$7.11B
Surprise %0.73%-0.00%0.16%0.56%-----

Net Income Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$493.60M$154.70M$341.20M$541.50M-----
Avg Forecast$469.89M$108.96M$212.70M$541.50M$680.80M$779.93M$954.91M$1.32B$1.64B
High Forecast$563.87M$140.14M$265.56M$676.08M$739.43M$931.55M$1.18B$1.39B$1.65B
Low Forecast$375.91M$77.78M$159.84M$406.92M$679.93M$759.83M$856.02M$1.26B$1.63B
Surprise %5.05%41.98%60.41%------

DXCM Forecast FAQ

Is DexCom stock a buy?

DexCom stock has a consensus rating of Buy, based on 50 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 38 Buy, 10 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that DexCom is a favorable investment for most analysts.

What is DexCom's price target?

DexCom's price target, set by 50 Wall Street analysts, averages $94.67 over the next 12 months. The price target range spans from $90 at the low end to $100 at the high end, suggesting a potential 34.04% change from the previous closing price of $70.63.

How does DexCom stock forecast compare to its benchmarks?

DexCom's stock forecast shows a 34.04% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (18.84%).

What is the breakdown of analyst ratings for DexCom over the past three months?

  • October 2025: 14.81% Strong Buy, 70.37% Buy, 14.81% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 11.11% Strong Buy, 74.07% Buy, 14.81% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 11.54% Strong Buy, 73.08% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.

What is DexCom’s EPS forecast?

DexCom's average annual EPS forecast for its fiscal year ending in December 2024 is $1.69, marking a 20.71% increase from the reported $1.4 in 2023. Estimates for the following years are $2.02 in 2025, $2.45 in 2026, $3.11 in 2027, and $3.85 in 2028.

What is DexCom’s revenue forecast?

DexCom's average annual revenue forecast for its fiscal year ending in December 2024 is $4.02B, reflecting a 11.04% increase from the reported $3.62B in 2023. The forecast for 2025 is $4.61B, followed by $5.31B for 2026, $6.26B for 2027, and $7.15B for 2028.

What is DexCom’s net income forecast?

DexCom's net income forecast for the fiscal year ending in December 2024 stands at $680.8M, representing an 25.72% increase from the reported $541.5M in 2023. Projections indicate $779.93M in 2025, $954.91M in 2026, $1.32B in 2027, and $1.64B in 2028.